Overcoming challenges in the diagnosis and treatment of myasthenia gravis

Amelia Evoli, Raffaele Iorio, Emanuela Bartoccioni

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In recent years, the discovery of new autoantigens and the use of sensitive assays have expanded the clinical spectrum of myasthenia gravis (MG). In particular, antibodies binding to clustered acetylcholine receptors and to the low-density lipoprotein receptor-related protein 4 have not only bridged a significant gap in diagnosis but also have relevant clinical implications. MG management includes different therapeutic options, from symptomatic agents as the only therapy in mildly affected cases to combined long-term immunosuppression and thymectomy in patients with severe disabling disease. MG biological diversity can influence the response to therapies and should be taken into account when planning treatment. Biologic agents are promising, though their use is currently limited to patients with refractory disease.

Original languageEnglish
Pages (from-to)157-168
Number of pages12
JournalExpert Review of Clinical Immunology
Volume12
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Myasthenia Gravis
LDL-Receptor Related Proteins
Thymectomy
LDL Receptors
Biodiversity
Autoantigens
Biological Factors
Cholinergic Receptors
Therapeutics
Immunosuppression
Antibodies

Keywords

  • AChR
  • Clustered-AChR
  • Immunosuppressants
  • Lrp4
  • MuSK
  • Myasthenia gravis
  • Thymectomy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Overcoming challenges in the diagnosis and treatment of myasthenia gravis. / Evoli, Amelia; Iorio, Raffaele; Bartoccioni, Emanuela.

In: Expert Review of Clinical Immunology, Vol. 12, No. 2, 01.02.2016, p. 157-168.

Research output: Contribution to journalArticle

@article{5ac9107be0724789a785015b5fab2dec,
title = "Overcoming challenges in the diagnosis and treatment of myasthenia gravis",
abstract = "In recent years, the discovery of new autoantigens and the use of sensitive assays have expanded the clinical spectrum of myasthenia gravis (MG). In particular, antibodies binding to clustered acetylcholine receptors and to the low-density lipoprotein receptor-related protein 4 have not only bridged a significant gap in diagnosis but also have relevant clinical implications. MG management includes different therapeutic options, from symptomatic agents as the only therapy in mildly affected cases to combined long-term immunosuppression and thymectomy in patients with severe disabling disease. MG biological diversity can influence the response to therapies and should be taken into account when planning treatment. Biologic agents are promising, though their use is currently limited to patients with refractory disease.",
keywords = "AChR, Clustered-AChR, Immunosuppressants, Lrp4, MuSK, Myasthenia gravis, Thymectomy",
author = "Amelia Evoli and Raffaele Iorio and Emanuela Bartoccioni",
year = "2016",
month = "2",
day = "1",
doi = "10.1586/1744666X.2016.1110487",
language = "English",
volume = "12",
pages = "157--168",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Overcoming challenges in the diagnosis and treatment of myasthenia gravis

AU - Evoli, Amelia

AU - Iorio, Raffaele

AU - Bartoccioni, Emanuela

PY - 2016/2/1

Y1 - 2016/2/1

N2 - In recent years, the discovery of new autoantigens and the use of sensitive assays have expanded the clinical spectrum of myasthenia gravis (MG). In particular, antibodies binding to clustered acetylcholine receptors and to the low-density lipoprotein receptor-related protein 4 have not only bridged a significant gap in diagnosis but also have relevant clinical implications. MG management includes different therapeutic options, from symptomatic agents as the only therapy in mildly affected cases to combined long-term immunosuppression and thymectomy in patients with severe disabling disease. MG biological diversity can influence the response to therapies and should be taken into account when planning treatment. Biologic agents are promising, though their use is currently limited to patients with refractory disease.

AB - In recent years, the discovery of new autoantigens and the use of sensitive assays have expanded the clinical spectrum of myasthenia gravis (MG). In particular, antibodies binding to clustered acetylcholine receptors and to the low-density lipoprotein receptor-related protein 4 have not only bridged a significant gap in diagnosis but also have relevant clinical implications. MG management includes different therapeutic options, from symptomatic agents as the only therapy in mildly affected cases to combined long-term immunosuppression and thymectomy in patients with severe disabling disease. MG biological diversity can influence the response to therapies and should be taken into account when planning treatment. Biologic agents are promising, though their use is currently limited to patients with refractory disease.

KW - AChR

KW - Clustered-AChR

KW - Immunosuppressants

KW - Lrp4

KW - MuSK

KW - Myasthenia gravis

KW - Thymectomy

UR - http://www.scopus.com/inward/record.url?scp=84957428439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957428439&partnerID=8YFLogxK

U2 - 10.1586/1744666X.2016.1110487

DO - 10.1586/1744666X.2016.1110487

M3 - Article

VL - 12

SP - 157

EP - 168

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 2

ER -